Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo‐controlled double‐blind trial
Kenneth E. Sherman, Maria Sjogren, Robin L. Creager, Melissa A. Damiano, Stephen Freeman, Scot Lewey, Dirk Davis, Spencer Root, Frederick L. Weber, Kamal G. Ishak, Zachary D. Goodman – 30 December 2003 – Hepatitis C is a major cause of liver disease leading to cirrhosis. Although interferon (IFN) is the only approved therapy, treatment is characterized by low response rates and dose‐limiting side effects.